Fundraising FoxAction Potential Venture Capital Ltd. — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.
BiotechHealthtechMedical DevicesChanhassen, US
Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)
BoardKlaus Veitinger(Director)inImran Eba(Executive Officer)in
Board seatJuan-Pablo Mas· per SEC Form D
Co-investorsOrbiMedHealthQuest CapitalSamsara BioCapitalSV Health InvestorsBrightEdge
Exo is a company backed by leading venture capital and corporate investors focused on innovative technologies, with particular emphasis on healthcare, bioelectronic medicines, materials science, and deep technology solutions.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Yusuf Haque(Founder)in
Board seatJuan-Pablo Mas· per SEC Form D · $10M raise · filed May 2025
Co-investorsBold Capital PartnersCreative VenturesPage One VenturesTDK VenturesIntel CapitalOSF Ventures+6 more
.jpeg){kind=logo}
Saluda Medical develops the Evoke spinal cord stimulation (SCS) system, which records the spinal cord's physiologic response to stimulation using Evoked Compound Action Potentials (ECAPs).
Deep TechHealthtechMedical DevicesBloomington, US
Greg Plamondon(Executive Officer)inKristin Caplice(Executive Officer)inBarry Regan(Executive Officer, Director)inJames Schuermann(Director, Executive Officer)Geoffrey Kinghorn(Director)
Board seatJuan-Pablo Mas· per SEC Form D
Co-investorsWellington ManagementFidelity InvestmentsREDMILET. Rowe Price
SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs.
BiotechHealthtechMedical DevicesValencia, US
Murthy Simhambhatla(CEO)inDavid Chernoff(Chief Medical Officer (MD))Yaakov Levine(PhD)inRohan Seth(Executive Officer)inKevin Tracey(Founder)
Board seatJuan-Pablo Mas· per SEC Form D
Co-investorsAlly Bridge GroupNew Enterprise Associates (NEA)Norwest Venture PartnersTopspin PartnersAsahi Kasei Corporate Venture CapitalCatalio Capital Management, LP+8 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.